CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in CNS Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −4 vs. Q4 2021
- Shares held
- 1.73M
- +558.5K (+47.5%) vs. Q4 2021
- Total value
- $589.0K
- −$239.0K (−28.9%) vs. Q4 2021
- New holders
- 4
- 6 more added
- Sold out
- 8
- 4 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Global Retirement Partners, LLC | 1,000 | $0 | 0.00% | 00.0% | Unchanged |
| Gradient Investments LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10 | $0 | 0.00% | 00.0% | Unchanged |
| Alpha Cubed Investments, LLC | 10,000 | $3.00K | 0.00% | −1,000−9.1% | Reduced |
| Wells Fargo & Company | 12,163 | $4.00K | 0.00% | +60+0.5% | Added |
| HighTower Advisors, LLC | 13,500 | $4.00K | 0.00% | +13,500 | New |
| Commonwealth Equity Services, LLC | 20,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 19,645 | $7.00K | 0.00% | +1,657+9.2% | Added |
| Cambridge Investment Research Advisors, Inc. | 25,250 | $9.00K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 25,143 | $9.00K | 0.00% | +25,143 | New |
| Tower Research Capital LLC (TRC) | 28,425 | $10.0K | 0.00% | +14,783+108.4% | Added |
| Northern Trust Corp | 32,094 | $11.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 41,087 | $14.0K | 0.00% | −716−1.7% | Reduced |
| Beacon Financial Advisory LLC | 40,000 | $14.0K | 0.01% | +40,000 | New |
| Citadel Advisors LLC | 55,231 | $18.0K | 0.00% | −26,703−32.6% | Reduced |
| Virtu Financial LLC | 111,749 | $38.0K | 0.00% | +111,749 | New |
| Geode Capital Management, LLC | 129,016 | $43.0K | 0.00% | +21,754+20.3% | Added |
| Bank of New York Mellon Corp | 234,892 | $80.0K | 0.00% | +205,134+689.3% | Added |
| Vanguard Group Inc | 427,703 | $146.0K | 0.00% | −181,706−29.8% | Reduced |
| Renaissance Technologies LLC | 506,532 | $173.0K | 0.00% | +358,832+242.9% | Added |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,513−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5,500−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,653−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −1,283−100.0% | Sold out |
| Capital Analysts, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −177−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |